Musi wa17 Mbudzi, 2025, Abbisko yakazivisa kuratidzwa kweposita rekushanda kwenguva refu, kuchengetedzeka uye mhedzisiro yakashumwa nevarwere kubva muongororo yepasi rose yePhase III MANEUVER yepimicotinib (ABSK021) muvarwere vane tenosynovial giant cell tumor (TGCT) paConnective Tissue Oncology Society (CTOS) 2025 Annual Meeting.
Pimicotinib mushonga mutsva, unonwiwa, unosarudza zvakanyanya, uye une simba weCSF-1R inhibitor yakagadzirwa yakazvimirira neAbbisko Therapeutics. Chidzidzo cheMANEUVER iongororo yepasi rose, ine nzvimbo dzakawanda, isina kurongeka, ine mapofu maviri, inodzorwa neplacebo ine zvikamu zvitatu, yakagadzirirwa kuongorora kushanda uye kuchengetedzeka kwepimicotinib muvarwere vane TGCT. Muganho wekutanga uye zvese zvakakosha zvechipiri zvakasangana muChikamu 1 pavhiki 25, uye mhedzisiro inoenderana yakapihwa paMusangano weGore weAmerican Society of Clinical Oncology (ASCO) wa2025. Muganho wekutanga iObjective Response rate (ORR) pakupera kweChikamu 1, sezvakaongororwa neBlind Independent Review Committee (BIRC) paRECIST v1.1. PaVhiki 25, pimicotinib yakaratidza kuvandudzika kwakakosha muORR zvichienzaniswa neplacebo paVhiki 25 (54.0% vs 3.2%, P<0.0001).
Zvakabuda pamusangano wegore negore weCTOS 2025 zvaive ruzivo rwekushanda kwenguva refu uye kuchengetedzeka kubva pakupedzwa kweChikamu chechipiri chechidzidzo cheMANEUVER. Nekutevera kwepakati pemwedzi 14.3, varwere vakagamuchira pimicotinib kubva pakutanga kwechidzidzo vakaratidza mhinduro dzakasimba uye dzinogara kwenguva refu dzegomarara. ORR nekomiti yekuongorora yakazvimiririra yakabvongodzwa (BIRC) paRECIST v1.1 yakawedzera kubva pa54% pavhiki 25 kusvika pa76.2% (95% CI: 63.8, 86.0), nevarwere vana vachiwana mhinduro yakakwana.
Zvichakadaro, chidzidzo ichi chakaratidzawo kuvandudzwa kuri kuramba kuchiitwa mukuongorora kwemigumisiro yekiriniki (COAs) zvine chekuita nehupenyu hwevarwere veTGCT, kusanganisira kufamba kwakasiyana-siyana, kuomarara, kurwadziwa, uye mashandiro emuviri. Mufananidzo wacho wakataurawo nezvemabhenefiti ehupenyu (QoL) akaongororwa neEQ-5D-5L visual analog scale (VAS). Varwere vari kurapwa pimicotinib vakaratidza kuvandudzika kweQoL kwe7.4% kubva pakutanga paVhiki 25, uko kwakawedzera kusvika pa13.1% paVhiki 73.
Pamusoro pezvo, varwere vakatanga vapihwa mushonga we placebo muChikamu 1 uye vakazochinja kuenda ku pimicotinib muChikamu 2 vakawanawo rubatsiro rwekiriniki, vachiwana ORR ye64.5% pakutevera kwepakati kwemwedzi 8.5, pamwe nekuvandudzika kukuru muCOAs.
Panyaya yekuchengetedzeka, huwandu hwepakati hwemushonga hwakaramba hwakakwira pa88.2% panguva yekurapwa. Zviitiko zvakawanda zvisina kunaka pakurapwa (TEAEs) zvaive zveGiredhi 1–2. Hapana zviratidzo zvitsva zvekuchengetedza zvakaonekwa, uye pakanga pasina humbowo hwekukuvadzwa nehepatic necholestatic, kukuvara kwechiropa kunokonzerwa nemishonga, kana ganda rakapindwa muropa zvishoma nezvishoma.
Zvinokosha kuziva kuti pamusangano weEuropean Society for Medical Oncology (ESMO) Congress 2025 wakaitwa muna Gumiguru gore rino, Purofesa Xiaohui Niu wekuBeijing Jishuitan Hospital, mukuru weongororo yeMANEUVER, akapa ruzivo urwu rwakakosha muhurukuro yemuromo.
Parizvino, kuchine miedzo yakawanda yekiriniki yehunyanzvi hutsva hwekurwisa gomarara muChina huri kutsvaga varwere. Kana muchida kubvunzana nezvemishonga mitsva netekinoroji, munogona kubata Dhipatimendi reBeijing South Region Oncology Hospital International.
Nhamba yefoni: 4008803716
Nhamba yeWeChat: 17801183037
Email ①：myimmnet@163.com
Email ②：100085_010@163.com
Nguva yekutumira: Mbudzi-18-2025